Merck’sVytorin may reduce CV events in CKD
This article was originally published in Scrip
Executive Summary
Merck & Co's Vytorin (ezetimibe/simvastatin) reduced the incidence of first major vascular events – defined as non-fatal heart attacks or cardiac death, stroke or any revascularisation procedure – by 16% in patients with chronic kidney disease (CKD), according to data from the five-year SHARP study.